Cizzle Biotechnology Holdings PLC (GB:CIZ) has released an update.
Cizzle Biotechnology Holdings PLC has announced further advancements in their partnership with Cizzle Bio Inc., a US-based firm set to market Cizzle’s innovative CIZ1B lung cancer biomarker test. Cizzle Bio Inc. has secured an initial investment and sought a 60-day extension for finalizing their binding agreement to accommodate additional strategic investment, promising to bolster Cizzle’s stake and accelerate the product’s market deployment. Investors and stakeholders can anticipate more updates as the collaboration progresses.
For further insights into GB:CIZ stock, check out TipRanks’ Stock Analysis page.
